Serum chromogranin a in prostate cancer
Akakura, K.
Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 11): 160-164
2002
ISSN/ISBN: 0047-1852 PMID: 12599564 Document Number: 542194
Document emailed within 1 workday
Related Documents
Khan, M.O.; Ather, M.H. 2011: Chromogranin A--serum marker for prostate cancer JPMA. Journal of the Pakistan Medical Association 61(1): 108-111Tarle, M. 1999: Serum chromogranin a in monitoring metastatic prostate cancer patients Anticancer Research 19(6c): 5663-5666
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Amayo, A.; Obara, W. 2004: Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate East African Medical Journal 81(1): 22-26
Miyamoto, S.; Jimbo, H.; Totsuka, Y.; Mashimo, T.; Umeyama, T.; Uehara, H.; Shinozaki, T. 1995: Change in serum prostate specific antigen values in men who had no evidence of prostate cancer on initial biopsy Hinyokika Kiyo. Acta Urologica Japonica 41(10): 767-770
Liang, J.; Zhao, X.-Z.; Shi, J.-Y.; Qiu, X.-F.; Zhang, Q.; Zhuang, J.-L.; Wang, W.; Deng, Y.-M.; Huang, H.-F.; Zhang, C.-W.; Guo, H.-Q. 2019: Combination of serum PSA assay, multi-parametric MRi and targeted prostate biopsy for prostate cancer screening in Nanjing Zhonghua Nan Ke Xue 25(9): 815-822
Yamaguchi, K.; Tanaka, M.; Kitagawa, N.; Kotake, T.; Yanagi, S.; Ito, H. 1989: The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers Hinyokika Kiyo. Acta Urologica Japonica 35(6): 987-991
Rahardjo, D.; Kamil, S.T.; Pakasi, L.S. 2000: Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 563-570
Giudici, A.M.; Sher, E.; Pelagi, M.; Clementi, F.; Zanini, A. 1992: Immunolocalization of secretogranin II, chromogranin A, and chromogranin B in differentiating human neuroblastoma cells European Journal of Cell Biology 58(2): 383-389
Stenman, U.H.; Leinonen, J.; Alfthan, H.; Rannikko, S.; Tuhkanen, K.; Alfthan, O. 1991: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Research 51(1): 222-226
Wu, C.T.; Chuang, C.K.; Chou, C.C.; Chu, S.H.; Chen, H.W.; Chen, C.S.; Chiang, Y.J.; Liao, S.K. 2000: The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml Chang Gung Medical Journal 23(3): 142-148
Biausque, F.; Jaboureck, O.; Devos, P.; D'Herbomez, M.; Hainaut, P.; Carré, A.; Mounier-Vehier, C. 2003: Clinical significant of serum chromogranin a levels for diagnosing pheochromocytoma in hypertensive patients Archives des Maladies du Coeur et des Vaisseaux 96(7-8): 780-783
Haese, A.; Partin, A.W.. 2001: New serum tests for the diagnosis of prostate cancer Drugs of Today 37(9): 607-616
Kanoh, Y.; Mashiko, T.; Danbara, M.; Takayama, Y.; Ohtani, S.; Egawa, S.; Baba, S.; Akahoshi, T. 2004: Changes in serum IgG oligosaccharide chains with prostate cancer progression Anticancer Research 24(5b): 3135-3139
Espinoza, A.R.; Lavi, J.; Otaño, N.; Arenilla, W.; León, R.; Espinoza, A.; Salvador, N.; León, A. 2019: Serum cellular inflammatory markers in the diagnosis of prostate cancer Archivos Espanoles de Urologia 72(7): 641-646
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Shinoda, I.; Takahashi, Y.; Takeuchi, T.; Kuriyama, M.; Ban, Y.; Kawada, Y.; Ito, Y.; Yamamoto, N.; Maeda, S.; Tada, K. 1991: Studies on 5-FU concentration in serum and prostate cancer tissue after oral administration of UFT Hinyokika Kiyo. Acta Urologica Japonica 37(7): 711-715
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654